Pegylated IFN-alpha 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B. (Q33868880)

29 July 2017

Pegylated IFN-alpha 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B. (English)

1 reference

29 July 2017

1 reference

Themistoklis Vassiliadis

1

1 reference

29 July 2017

Kalliopi Patsiaoura

2

1 reference

29 July 2017

Konstantinos Tziomalos

3

1 reference

29 July 2017

Theodoros Gkiourtzis

4

1 reference

29 July 2017

Olga Giouleme

5

1 reference

29 July 2017

Nikolaos Grammatikos

6

1 reference

29 July 2017

Despoina Rizopoulou

7

1 reference

29 July 2017

Nikolaos Nikolaidis

8

1 reference

29 July 2017

Panagiotis Katsinelos

9

1 reference

29 July 2017

Eleni Orfanou-Koumerkeridou

10

1 reference

29 July 2017

Nikolaos Eugenidis

11

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

World Journal of Gastroenterology

29 July 2017

1 reference

29 July 2017

12

1 reference

29 July 2017

15

1 reference

29 July 2017

2417-2422

1 reference

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4088081

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4088081

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4088081

Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4088081

Management of hepatitis B: 2000--summary of a workshop

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4088081

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4088081

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4088081

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4088081

Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B.

5 July 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I15.2417

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I15.2417

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I15.2417

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I15.2417

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I15.2417

Pegylated interferons for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I15.2417

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I15.2417

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I15.2417

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I15.2417

The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I15.2417

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I15.2417

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I15.2417

Effect of interferon alpha on hepatitis B virus replication and gene expression in transiently transfected human hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I15.2417

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I15.2417

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V12.I15.2417

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4088081

29 October 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/16688836

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3748/WJG.V12.I15.2417

1 reference

29 July 2017

1 reference

29 July 2017

1 reference